Roger Schibli
Paul Scherrer Institute
Center for Radiopharmaceutical Sciences ETH-PSI-USZ
Villigen-PSI
5232, Switzerland
Switzerland
Name/email consistency: high
- PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues. Däpp, S., Müller, C., Garayoa, E.G., Bläuenstein, P., Maes, V., Brans, L., Tourwé, D.A., Schibli, R. EJNMMI. Res (2012)
- Synthesis and in vitro characterization of organometallic rhenium and technetium glucose complexes against Glut 1 and hexokinase. Schibli, R., Dumas, C., Petrig, J., Spadola, L., Scapozza, L., Garcia-Garayoa, E., Schubiger, P.A. Bioconjug. Chem. (2005)
- Syntheses and characterization of dicarbonyl-nitrosyl complexes of technetium(I) and rhenium(I) in aqueous media: spectroscopic, structural, and DFT analyses. Schibli, R., Marti, N., Maurer, P., Spingler, B., Lehaire, M.L., Gramlich, V., Barnes, C.L. Inorg. Chem (2005)
- Steps toward high specific activity labeling of biomolecules for therapeutic application: preparation of precursor [(188)Re(H(2)O)(3)(CO)(3)](+) and synthesis of tailor-made bifunctional ligand systems. Schibli, R., Schwarzbach, R., Alberto, R., Ortner, K., Schmalle, H., Dumas, C., Egli, A., Schubiger, P.A. Bioconjug. Chem. (2002)
